Segment 2 - Bringing Latest Innovations to the Public

Jianda Yuan, MD, PhD, explains the importance of bringing the latest innovations to the public and how more data are showing promising immunologic and clinical responses for different types of cancer.

Medical conferences are presenting premium data from more phase I and II studies and not only are organizations picking up on the studies of PD-1 and PD-L1, but so is the mainstream media, which brings the data to different levels of society.

Kimberly Shafer-Weaver, PhD, added that there needs to be more education of physicians regarding how immunotherapy can be added into the regime for a patient.

“And it is amazing that, you know, right now, standard of care is not immunotherapy, but we are really finding that quickly if it is something that should be added and with standard of care early on when the patient has a good ability to respond because an immune system is intact,” Dr Shafer-Weaver said.